suzhou, may 22, 2020 - alphamab oncology (stock code: 9966hk) announced that jiangsu alphamab biopharmaceuticals co., ltd. (“jiangsu alphamab” or “alphamab oncology”), a wholly-owned subsidiary of the company, has entered a partnership agreement with inxmed (shanghai) co., ltd. (“inxmed”), to jointly develop the combination therapy of pd-l1 / ctla-4 bispecific antibody kn046 and focal adhesion kinase inhibitor in10018. this collaboration will first evaluate the safety, tolerability, and efficacy of the combination of kn046 and in10018 in patients with pancreatic cancer.
dr. ting xu, founder, chairman and ceo of alphamab oncology commented, “kn046 is currently the world's first pd-l1 / ctla-4 bispecific antibody. since obtaining ind approval in 2018, we have continuously expanded the development of its indications in australia, china, and the united states. its safety and initial efficacy have been validated. alphamab oncology is actively exploring various combination therapies to unlock the great potential of kn046. pancreatic cancer is known as the “king of cancer” and responds very poorly to immunotherapy. kn046 showed promising efficacy signal for advanced last line pancreatic cancer in a phase i clinical trial. we look forward to exploring the synergistic effect of combination of kn046 and the unique mechanism of in0018 to bring hope to pancreatic cancer patients worldwide.”
dr. zaiqi wang, chairman and ceo of inxmed commented, “in10018 has great potential to become the best candidate for combination with many existing treatment options and is currently undergoing clinical studies for multiple indications in china, the united states and australia. following our collaboration with two global leading pharmaceutical companies, roche and merck, on combination therapies, we are excited to partner with the innovative oncology biopharma alphamab oncology to conduct in-depth study on the combination of in10018 and the bispecific antibody kn046 to provide more treatment options for the significantly under-addressed global diseases such as pancreatic cancer. ”
kn046 is the world's first recombinant humanized pd-l1/ctla-4 bispecific antibody independently developed by jiangsu alphamab. its innovative designs include: a proprietary ctla-4 domain antibody with a significantly improved safety profile; a bispecific antibody fused with pd-l1 antibody; engineered to target the tumor microenvironment with high pd-l1 expression, and treg clearing function. the preclinical and clinical study results of kn046 have shown promising efficacy and significantly reduced toxicity to human peripheral system, with the potential to become the backbone of next generation immuno-oncology therapy in the future.
previously, kn046's phase i clinical trials in australia and china have shown a preliminary profile of good safety and promising efficacy, and several phase ii clinical trials are ongoing in china for nsclc, tnbc, escc and pancreatic cancer.
n10018, formerly known as bi853520, is a potent and selective atp-competitive focal adhesion kinase (fak) small molecule inhibitor under clinical development stage in united states, australia, and china. inxmed owns the exclusive global rights for development and commercialization. early clinical data of in10018 has demonstrated a favorable safety profile and promising efficacy signals against a number of tumor types. emerging science also showed that fak inhibitors, such as in10018, could potentially overcome fibrotic barrier and immune tolerance, boosting multi-modalities including targeted therapy, chemotherapy, immune-therapy and radiation therapy.
about alphamab oncology
alphamab oncology is a biopharmaceutical company focusing on innovative biologics medicine for oncology. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.
alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. its highly differentiated in-house pipeline consists of eight anti-cancer drug candidates, four of which have advanced into phase i – iii clinical development phases in china, us and japan.
the company also has state-of-the-art manufacturing capability designed and built to meet nmpa and eu/fda’s cgmp standards.
alphamab oncology is committed to further develop its robust pipeline in oncology/immunology to benefit patients around the world. visit http://www.alphamabonc.com for more information.
founded in the end of 2018, inxmed is a clinical-stage biotech company. inxmed focuses building a highly effective translational and proof-of-concept engine by relying on biology of disease as driving force for innovation, with the aspiration of becoming a china-based innovative pharma with global impact. inxmed has completed the series a round and raised over ten million us dollars, and established a highly capable research and development team across shanghai, beijing, united states, canada and australia, build a strong pipeline aiming at becoming “best combo r&d” with global ip right. inxmed has established partnerships with multiple multinational pharma companies including merck, roche and boehringer-ingelheim.
alphamab oncology forward-looking statements
this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.